128 related articles for article (PubMed ID: 16989610)
1. HIV type 1 inhibition by protein kinase C modulatory compounds.
Warrilow D; Gardner J; Darnell GA; Suhrbier A; Harrich D
AIDS Res Hum Retroviruses; 2006 Sep; 22(9):854-64. PubMed ID: 16989610
[TBL] [Abstract][Full Text] [Related]
2. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART.
Kulkosky J; Culnan DM; Roman J; Dornadula G; Schnell M; Boyd MR; Pomerantz RJ
Blood; 2001 Nov; 98(10):3006-15. PubMed ID: 11698284
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of HIV receptor and co-receptor down-regulation by prostratin: role of conventional and novel PKC isoforms.
Hezareh M; Moukil MA; Szanto I; Pondarzewski M; Mouche S; Cherix N; Brown SJ; Carpentier JL; Foti M
Antivir Chem Chemother; 2004 Jul; 15(4):207-22. PubMed ID: 15457682
[TBL] [Abstract][Full Text] [Related]
4. Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue.
Biancotto A; Grivel JC; Gondois-Rey F; Bettendroffer L; Vigne R; Brown S; Margolis LB; Hirsch I
J Virol; 2004 Oct; 78(19):10507-15. PubMed ID: 15367617
[TBL] [Abstract][Full Text] [Related]
5. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
De la Torre-Tarazona HE; Jiménez R; Bueno P; Camarero S; Román L; Fernández-García JL; Beltrán M; Nothias LF; Cachet X; Paolini J; Litaudon M; Alcami J; Bedoya LM
Biochem Pharmacol; 2020 Jul; 177():113937. PubMed ID: 32224142
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of phorbol-13-monoesters on human immunodeficiency virus reactivation.
Márquez N; Calzado MA; Sánchez-Duffhues G; Pérez M; Minassi A; Pagani A; Appendino G; Diaz L; Muñoz-Fernández MA; Muñoz E
Biochem Pharmacol; 2008 Mar; 75(6):1370-80. PubMed ID: 18241838
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the interaction of ingenol 3-angelate with protein kinase C.
Kedei N; Lundberg DJ; Toth A; Welburn P; Garfield SH; Blumberg PM
Cancer Res; 2004 May; 64(9):3243-55. PubMed ID: 15126366
[TBL] [Abstract][Full Text] [Related]
8. Prostratin induces HIV activation and downregulates HIV receptors in peripheral blood lymphocytes.
Rullas J; Bermejo M; García-Pérez J; Beltán M; González N; Hezareh M; Brown SJ; Alcamí J
Antivir Ther; 2004 Aug; 9(4):545-54. PubMed ID: 15456086
[TBL] [Abstract][Full Text] [Related]
9. Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR.
Abreu CM; Price SL; Shirk EN; Cunha RD; Pianowski LF; Clements JE; Tanuri A; Gama L
PLoS One; 2014; 9(5):e97257. PubMed ID: 24827152
[TBL] [Abstract][Full Text] [Related]
10. Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV.
Rochat MA; Schlaepfer E; Speck RF
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928016
[TBL] [Abstract][Full Text] [Related]
11. Prostratin as a new therapeutic agent targeting HIV viral reservoirs.
Hezareh M
Drug News Perspect; 2005 Oct; 18(8):496-500. PubMed ID: 16391719
[TBL] [Abstract][Full Text] [Related]
12. Identification of proximal biomarkers of PKC agonism and evaluation of their role in HIV reactivation.
Vemula SV; Maxwell JW; Nefedov A; Wan BL; Steve J; Newhard W; Sanchez RI; Tellers D; Barnard RJ; Blair W; Hazuda D; Webber AL; Howell BJ
Antiviral Res; 2017 Mar; 139():161-170. PubMed ID: 27889530
[TBL] [Abstract][Full Text] [Related]
13. SJ23B, a jatrophane diterpene activates classical PKCs and displays strong activity against HIV in vitro.
Bedoya LM; Márquez N; Martínez N; Gutiérrez-Eisman S; Alvarez A; Calzado MA; Rojas JM; Appendino G; Muñoz E; Alcamí J
Biochem Pharmacol; 2009 Mar; 77(6):965-78. PubMed ID: 19100719
[TBL] [Abstract][Full Text] [Related]
14. In vitro effects of the small-molecule protein kinase C agonists on HIV latency reactivation.
Brogdon J; Ziani W; Wang X; Veazey RS; Xu H
Sci Rep; 2016 Dec; 6():39032. PubMed ID: 27941949
[TBL] [Abstract][Full Text] [Related]
15. Novel indolocarbazole protein kinase C inhibitors prevent reactivation of HIV-1 in latently infected cells.
Pätzold S; Schneider J; Rudolph C; Marmé D; Schächtele C
Antiviral Res; 1993 Dec; 22(4):273-83. PubMed ID: 8279816
[TBL] [Abstract][Full Text] [Related]
16. Expression of CD4 controls the susceptibility of THP-1 cells to infection by R5 and X4 HIV type 1 isolates.
Konopka K; Düzgüneş N
AIDS Res Hum Retroviruses; 2002 Jan; 18(2):123-31. PubMed ID: 11839145
[TBL] [Abstract][Full Text] [Related]
17. BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1.
Gohda J; Suzuki K; Liu K; Xie X; Takeuchi H; Inoue JI; Kawaguchi Y; Ishida T
Sci Rep; 2018 Feb; 8(1):3521. PubMed ID: 29476067
[TBL] [Abstract][Full Text] [Related]
18. Activation of latent HIV-1 expression by the potent anti-tumor promoter 12-deoxyphorbol 13-phenylacetate.
Bocklandt S; Blumberg PM; Hamer DH
Antiviral Res; 2003 Jul; 59(2):89-98. PubMed ID: 12895692
[TBL] [Abstract][Full Text] [Related]
19. Role of protein kinase C in the regulation of prostaglandin synthesis in human endothelium.
Garcia JG; Stasek J; Natarajan V; Patterson CE; Dominguez J
Am J Respir Cell Mol Biol; 1992 Mar; 6(3):315-25. PubMed ID: 1540395
[TBL] [Abstract][Full Text] [Related]
20. Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo.
Beans EJ; Fournogerakis D; Gauntlett C; Heumann LV; Kramer R; Marsden MD; Murray D; Chun TW; Zack JA; Wender PA
Proc Natl Acad Sci U S A; 2013 Jul; 110(29):11698-703. PubMed ID: 23812750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
